Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

BioVeris licenses Baxter's vaccine portfolio



13th August,2005:BioVeris Corporation has completed a Technology License Agreement with Baxter Healthcare Corporation for exclusive patent rights to a broad portfolio of vaccine candidates.

Vaccines covered by the agreement include those for the prevention of diseases caused by Group A streptococci, Group B streptococci, Pneumococci, Group B meningococci, anthrax bacilli and urinary tract infection (UTI) associated E. coli, a BioVeris release said.

Under the Agreement, BioVeris receives exclusive rights to patents or know-how related to the manufacture, production, use and commercialization of the vaccine candidates. The company paid a license issue fee and may also make additional future payments for patent costs, milestone fees for initiating and completing human clinical trials and receiving regulatory approvals.

BioVeris is also required to pay royalties on product sales and beginning in 2010, is required to pay a minimum annual royalty that is creditable against any other milestone payments and royalties.

The vaccine portfolio covered by the agreement is based on a conjugate technology platform and also includes recombinant protein antigens. The vaccine candidates are expected to complement and expand the existing intellectual property and vaccine candidates at BioVeris, which now has additionl comprehensive candidates for vaccines against bacterial meningitis, including that of streptococcal, pneumococcal and meningococcal origin.

BioVeris' vaccine candidate portfolio addresses different organisms, including group A streptococci (of strep throat, impetigo, flesh-eating bacteria and streptococcal toxic shock syndrome), group B streptococci (of sepsis, meningitis, and pneumonia in newborns and adults), group B meningococci (of sepsis, meningitis, and pneumonia at any age), and E. coli (of UTI, predominantly for women).

In addition, the vaccine candidate for disease caused by anthrax bacilli may provide a safer and better anthrax vaccine based on a recombinant protective antigen. Each of these vaccines could be candidates for entry into billion dollar global markets.

BioVeris Corporation is a global integrated health care company developing proprietary technologies in diagnostics and vaccinology. BioVeris is headquartered in Gaithersburg, Maryland.

Baxter International Inc. is a global healthcare company with 2004 sales of 9.5 billion. With approximately 48,000 employees, Baxter applies its expertise in medical devices, pharmaceuticals and biotechnology.

Pharma News Headlines

Cancer News

Cardiac News


Pharma industry news


Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Pfizer files NDA for Sutent in US

BioVeris licenses Baxter's vaccine portfolio

TheraQuest receives 2nd Orphan Drug status for neuralgia drug

Real-time glucose monitoring device approved in US

Halozyme gets FDA nod for bladder cancer therapy

Migenix to commence phase 2b studies in hep C therapy

Barr gets US FDA okay for clonazepam tabs

Anorexia drug study results positive: Par

GlaxoSmithKline begins phase III trials of new HIV drug

Ranbaxy's 7 anti retrovirals included in WHO list

FDA tightens restrictions on acne drug

Voglibose tabs launched in Japan

Remicade researcher gifts $ 105m to NYU

Par loses ondansetron case to GSK

Mistral starts clinical studies for generic

Carl Icahn sells Mylan shares

Florida sues Mylan, Teva and Watson

Dey and Connecticut settle pricing dispute

Germany set to stop rabies crossing borders

Office to review DTC drug advertisements in US

British docs to be trained in communication, safety

FDA okays acrylic lens for cataract patients 

Corautus to go ahead with angina drug studies 

Americans turn the low-fat way

Chemicals in plastics pose danger

US committee probes doctors’ complicity with Wall Street analysts

Meda buys out rival Viatris

US FDA nod for new levofloxacin regimen to treat acute bacterial sinusitis

Pozen files for new migraine treatment

New therapy for pancreatic cancer under review

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers



Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us